Core Insights - Bristol Myers Squibb's (BMY) revenue performance in 2025 shows a transition with growth from new products offsetting declines in legacy drugs [1][9] - Total revenues were flat year over year, with a 17% increase in sales from the growth portfolio and a 15% decline in legacy products due to generic competition [1][9] Legacy and Growth Portfolio - The legacy portfolio, including drugs like Eliquis, Revlimid, Pomalyst, Sprycel, and Abraxane, is under pressure due to loss of exclusivity for four drugs [2] - The growth portfolio, featuring drugs such as Opdivo, Opdivo Qvantig, Orencia, and others, is crucial for maintaining revenue stability [2] Immuno-Oncology and Key Drug Performance - The immuno-oncology (IO) portfolio, particularly Opdivo, continues to show strong sales momentum due to label expansions and market share growth [3] - Opdivo Qvantig's approval has contributed to growth, with robust initial uptake across approved tumor types in the U.S. [4] - Reblozyl has achieved an annualized sales run rate above $2 billion, while Breyanzi has surpassed $1 billion in annualized sales [5] Future Outlook and Competition - Management anticipates a further decline of 12-16% in legacy sales for 2026, guiding revenues to $46.0-$47.5 billion [7] - BMY faces increasing competition in oncology from companies like Merck, particularly with the success of Keytruda [8][10] Market Performance and Valuation - BMY's shares have gained 12.7% over the past year, compared to the industry's growth of 19.6% [13] - The company is trading at a price/earnings ratio of 9.80x forward earnings, which is lower than the large-cap pharma industry's average of 18.82x [14] Earnings Estimates - The Zacks Consensus Estimate for 2026 EPS has increased to $6.15 from $6.04, while the estimate for 2027 has risen to $5.94 [17]

Full Year and Q4 2025 Financial Results February 11, 2026 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and ne ...

Company Overview - Sanofi is a global healthcare leader engaged in the research, development, manufacturing, and marketing of pharmaceutical products, focusing on innovative solutions in vaccines, rare diseases, multiple sclerosis, oncology, immunology, and cardiovascular diseases [1] - The company competes with other pharmaceutical giants like Pfizer and GlaxoSmithKline [1] Recent Developments - Sanofi achieved a significant milestone with the approval of two innovative medicines, Myqorzo and Redemplo, by China's National Medical Products Administration, indicating a strong commitment to the Chinese market [3] - Myqorzo treats obstructive hypertrophic cardiomyopathy, while Redemplo targets triglyceride levels in patients with familial chylomicronemia syndrome [3] Stock Performance - The current stock price of Sanofi (SNY) on NASDAQ is $46.59, reflecting a decrease of approximately 1.86%, with a trading range from $46.49 to $47.03 [4] - Over the past year, the stock has seen a high of $60.12 and a low of $44.62, indicating some volatility [4] - Sanofi's market capitalization is approximately $113.5 billion, with a trading volume of 1,517,570 shares, reflecting a strong position in the pharmaceutical industry despite recent fluctuations [5] Analyst Ratings - Deutsche Bank maintained a "Buy" rating for Sanofi, with the stock trading at $46.63, but adjusted the price target from EUR 110 to EUR 105, indicating a more conservative outlook [2][6]

Financial Performance & Goals - Royalty Pharma's 2025 Portfolio Receipts guidance midpoint is $3225 million, representing approximately 15% growth[7] - The company's Return on Invested Capital was 157% and Return on Invested Equity was 229% in Q3 2025 LTM (Last Twelve Months)[7] - The company aims for Portfolio Receipts of over $47 billion by 2030, implying a CAGR of 10% or more from 2020[18] - The company projects approximately $30 billion of capital deployment capacity from H2 2025 to 2030[73] Capital Allocation & Investment - The company announced $47 billion in new royalty deals in 2025, with $26 billion in Capital Deployment[7] - The company repurchased $12 billion of shares and increased dividends by a mid-single digit percentage[7] - The company deployed approximately 65% of capital on approved products since 2012[45] - The company announced four synthetic royalty deals in 2025, totaling $2075 million in announced value[36] Portfolio & Pipeline - The company's portfolio includes therapies like Tremfya, which received FDA and EC approval for Crohn's disease and EC approval for ulcerative colitis[59] - The company anticipates peak royalties ranging from approximately $180 million to $340 million from daraxonrasib for pancreatic cancer[62, 64] - The company expects peak royalties of over $400 million from frexalimab for multiple sclerosis[62, 64]

Core Insights - Cytokinetics, Incorporated (CYTK) received FDA approval for its lead candidate aficamten, now branded as Myqorzo, for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) [2][10] - This approval marks a significant transition for Cytokinetics from a development-stage biotech to a commercial-stage company [2][8] - Myqorzo demonstrated significant improvements in exercise capacity in clinical trials, with a peak oxygen uptake increase of 1.8 mL/kg/min compared to placebo [5][10] Company Overview - Myqorzo is an allosteric, reversible inhibitor of cardiac myosin motor activity, targeting the underlying pathophysiology of oHCM [4] - The drug is expected to be available in the U.S. by January 2026, with regulatory progress in Europe and China also noted [11][12] - The approval positions Cytokinetics as a key player in the specialty cardiology market, which has historically offered limited pharmacologic options for symptomatic patients [10] Market Potential - The oHCM market represents a substantial commercial opportunity, with over 300,000 diagnosed patients in the U.S. and an estimated additional 400,000 to 800,000 undiagnosed individuals [11] - Myqorzo will face competition from Bristol Myers Squibb's Camzyos, which has performed well since its approval in 2022 [12][13] Clinical Data - The pivotal phase III study SEQUOIA-HCM provided robust support for Myqorzo's approval, showing statistically significant improvements in exercise capacity [5] - Safety data indicated that Myqorzo was generally well tolerated, with serious adverse events occurring in 5.6% of patients compared to 9.3% in the placebo group [6] Future Outlook - The drug's commercialization success will be crucial for Cytokinetics, as it aims to capitalize on the growing demand for effective treatments in the oHCM market [12] - The company is currently ranked 3 (Hold) by Zacks, with potential for upward movement as it transitions into a commercial entity [14]

Company Overview - Cytokinetics, Incorporated is a late-stage biotechnology company focused on muscle biology therapeutics for serious cardiovascular and neuromuscular diseases, with a differentiated pipeline of muscle activators and inhibitors [6] - The company is currently engaged in several phase 3 clinical trials, positioning itself as a potential leader in addressing unmet medical needs in heart failure and related conditions [6] Recent Developments - Cytokinetics recently achieved a significant milestone by receiving a $7.5 million payment from Sanofi after the approval of Myqorzo for treating adults with obstructive hypertrophic cardiomyopathy in China, with potential for up to $142.5 million more plus royalties from the agreement [8] - The company is awaiting a decision from the FDA on aficamten for patients with obstructive hypertrophic cardiomyopathy, which would mark its first FDA approval [9] Insider Transactions - B. Lynne Parshall, a Director at Cytokinetics, reported the sale of 5,000 shares valued at approximately $323,650 on November 19, 2025, representing 17.9% of her direct ownership prior to the transaction [4][7] - Following the sale, Parshall's remaining direct holdings are valued at approximately $1.49 million based on the closing price of $64.79 [2] Stock Performance - The stock has shown a total return of approximately 27.36% over the past year, outperforming the S&P 500's 13% gain [7] - The recent sale of shares by Parshall aligns with her historical median sale size, although the percentage of holdings sold has increased as the share base has declined [3]